Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.
Goldstein
David M
DM
Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, California 94304, USA. david-m.goldstein@roche.com
Kuglstatter
Andreas
A
Lou
Yan
Y
Soth
Michael J
MJ
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000201:enzymology; D002908:Chronic Disease; D017322:Clinical Trials, Phase II as Topic; D018360:Crystallography, X-Ray; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000201:enzymology; D008958:Models, Molecular; D015394:Molecular Structure; D010671:Phenylurea Compounds / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D011485:Protein Binding; D011565:Psoriasis / Q000188:drug therapy / Q000201:enzymology; D011728:Pyridones / Q000737:chemistry / Q000627:therapeutic use; D011743:Pyrimidines / Q000737:chemistry / Q000627:therapeutic use; D016896:Treatment Outcome; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
D004791:Enzyme Inhibitors; D007211:Indoles; D010671:Phenylurea Compounds; D011728:Pyridones; D011743:Pyrimidines; C499748:SCIO-469; C517771:VX 702; C533858:pamapimod; D048051:p38 Mitogen-Activated Protein Kinases